Host factors affecting the outcome of treatment of hepatitis C

Raffaele Bruno, Paolo Sacchi, Laura Maiocchi, Cristina Zocchetti, Gaetano Filice

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The development of peginterferon and ribavirin combination therapy has significantly improved the sustained virologic response (SVR) rates in patients with chronic hepatitis C. However, poor patient adherence to therapy negatively influences drug levels and drug exposure, often preventing the development of an inhibitory drug level. To optimize patient adherence, the clinician must recognize factors predicting low adherence and negotiate a treatment plan that the patient understands and to which he or she commits. If adverse effects become intolerable, continuing patients on a reduced dose rather than withdrawing treatment seems to confer considerable advantage in preserving the chance for attaining an SVR. Results of a head-to-head comparison have demonstrated the possibility that, in cases of dose reduction, levels of peginterferon alfa-2a could remain above the limit of detection, whereas those of peginterferon alfa-2b might not.

Original languageEnglish
JournalReviews in Gastroenterological Disorders
Volume4
Issue numberSUPPL. 1
Publication statusPublished - 2004

Fingerprint

Hepatitis C
Patient Compliance
Pharmaceutical Preparations
Withholding Treatment
Ribavirin
Chronic Hepatitis C
Limit of Detection
Therapeutics
Sustained Virologic Response

Keywords

  • Adherence
  • Adverse effects
  • Hepatitis C
  • Peginterferon
  • Pharmacokinetics
  • Ribavirin

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Host factors affecting the outcome of treatment of hepatitis C. / Bruno, Raffaele; Sacchi, Paolo; Maiocchi, Laura; Zocchetti, Cristina; Filice, Gaetano.

In: Reviews in Gastroenterological Disorders, Vol. 4, No. SUPPL. 1, 2004.

Research output: Contribution to journalArticle

@article{93cece128d1b4e2bb9863a3d7a85d3bd,
title = "Host factors affecting the outcome of treatment of hepatitis C",
abstract = "The development of peginterferon and ribavirin combination therapy has significantly improved the sustained virologic response (SVR) rates in patients with chronic hepatitis C. However, poor patient adherence to therapy negatively influences drug levels and drug exposure, often preventing the development of an inhibitory drug level. To optimize patient adherence, the clinician must recognize factors predicting low adherence and negotiate a treatment plan that the patient understands and to which he or she commits. If adverse effects become intolerable, continuing patients on a reduced dose rather than withdrawing treatment seems to confer considerable advantage in preserving the chance for attaining an SVR. Results of a head-to-head comparison have demonstrated the possibility that, in cases of dose reduction, levels of peginterferon alfa-2a could remain above the limit of detection, whereas those of peginterferon alfa-2b might not.",
keywords = "Adherence, Adverse effects, Hepatitis C, Peginterferon, Pharmacokinetics, Ribavirin",
author = "Raffaele Bruno and Paolo Sacchi and Laura Maiocchi and Cristina Zocchetti and Gaetano Filice",
year = "2004",
language = "English",
volume = "4",
journal = "Reviews in Gastroenterological Disorders",
issn = "1533-001X",
publisher = "MedReviews LLC",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Host factors affecting the outcome of treatment of hepatitis C

AU - Bruno, Raffaele

AU - Sacchi, Paolo

AU - Maiocchi, Laura

AU - Zocchetti, Cristina

AU - Filice, Gaetano

PY - 2004

Y1 - 2004

N2 - The development of peginterferon and ribavirin combination therapy has significantly improved the sustained virologic response (SVR) rates in patients with chronic hepatitis C. However, poor patient adherence to therapy negatively influences drug levels and drug exposure, often preventing the development of an inhibitory drug level. To optimize patient adherence, the clinician must recognize factors predicting low adherence and negotiate a treatment plan that the patient understands and to which he or she commits. If adverse effects become intolerable, continuing patients on a reduced dose rather than withdrawing treatment seems to confer considerable advantage in preserving the chance for attaining an SVR. Results of a head-to-head comparison have demonstrated the possibility that, in cases of dose reduction, levels of peginterferon alfa-2a could remain above the limit of detection, whereas those of peginterferon alfa-2b might not.

AB - The development of peginterferon and ribavirin combination therapy has significantly improved the sustained virologic response (SVR) rates in patients with chronic hepatitis C. However, poor patient adherence to therapy negatively influences drug levels and drug exposure, often preventing the development of an inhibitory drug level. To optimize patient adherence, the clinician must recognize factors predicting low adherence and negotiate a treatment plan that the patient understands and to which he or she commits. If adverse effects become intolerable, continuing patients on a reduced dose rather than withdrawing treatment seems to confer considerable advantage in preserving the chance for attaining an SVR. Results of a head-to-head comparison have demonstrated the possibility that, in cases of dose reduction, levels of peginterferon alfa-2a could remain above the limit of detection, whereas those of peginterferon alfa-2b might not.

KW - Adherence

KW - Adverse effects

KW - Hepatitis C

KW - Peginterferon

KW - Pharmacokinetics

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=2942650861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942650861&partnerID=8YFLogxK

M3 - Article

VL - 4

JO - Reviews in Gastroenterological Disorders

JF - Reviews in Gastroenterological Disorders

SN - 1533-001X

IS - SUPPL. 1

ER -